XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
XCSport体育:Media Reports
XCSport体育:Media Enquiry
2024-11-28
Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG
2024-11-27
Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43
2024-11-24
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43
2024-11-23
Henlius Receives the FDA IND Approval for Its EGFR-Targeting ADC Candidate HLX42
2024-11-22
Henlius Announces Upcoming Mini Oral Presentation and Five Posters at the ESMO Asia 2023
2024-11-20
Henlius’ Second U.S. Clinical Investigators Meeting: In-Depth Exploration of Small Cell Lung Cancer Treatment Innovations
2024-11-15
Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 Billion, Profitability Further Improved
2024-10-31
Phase 3 Clinical Study of HANSIZHUANG in Combination with Chemotherapy for Treatment on Patients with non-squamous NSCLC Met Primary Endpoint
2024-10-30
Henlius Showcases Innovations and Strengthens International Collaboration at CPHI Worldwide 2023
1
2
3
4
...
8